Compare · BRKR vs PRPO
BRKR vs PRPO
Side-by-side comparison of Bruker Corporation (BRKR) and Precipio Inc. (PRPO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRKR and PRPO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $8.55B, about 211.4x PRPO ($40.4M).
- Over the past year, BRKR is up 38.2% and PRPO is up 105.0% - PRPO leads by 66.8 points.
- BRKR has been more active in the news (10 items in the past 4 weeks vs 3 for PRPO).
- BRKR has more recent analyst coverage (22 ratings vs 0 for PRPO).
- Company
- Bruker Corporation
- Precipio Inc.
- Price
- $55.15+0.46%
- $22.96+0.31%
- Market cap
- $8.55B
- $40.4M
- 1M return
- +23.34%
- -19.44%
- 1Y return
- +38.22%
- +105.00%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 10
- 3
- Recent ratings
- 22
- 0
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Precipio Inc.
Precipio, Inc., a cancer diagnostics and reagent technology company, provides diagnostic products and services in the United States oncology market. Its product consists of clinical diagnostic services. The company's clinical diagnostic services focus on the diagnosis of different hematopoietic or blood-related cancers to oncologists. Its cytogenetics media IV-Cell enables laboratories to arrive at more accurate results; HemeScreen panel enables hospitals and laboratories to run an important genetic mutation test; and ICE-COLD-PCR enables detection of abnormalities in blood samples. The company also operates a cancer diagnostic laboratory located in New Haven, Connecticut. It sells ICE-COLD-PCR technology kits to bio-pharma customers, clinical research, HemeScreen, and COVID-19 antibody tests. The company serves oncologists, hospitals, reference laboratories, physician-office labs, and pharma and biotech companies. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, such as the Yale School of Medicine, Harvard's Dana-Farber Cancer Institute, and the University of Pennsylvania. The company is based in New Haven, Connecticut.
Latest BRKR
- Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
- Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
- Wolfe Research resumed coverage on Bruker
- Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
- SEC Form SD filed by Bruker Corporation
- Amendment: Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI
- Bruker Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Bernard Thierry was granted 2,886 shares (SEC Form 4)
- EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 2,000 shares at a strike of $22.19 and sold $87,800 worth of shares (2,000 units at $43.90) as part of a pre-agreed trading plan (SEC Form 4)
Latest PRPO
- Precipio to Present at the Planet MicroCap Las Vegas
- Director Sandberg Richard A sold $22,517 worth of shares (900 units at $25.02) (SEC Form 4)
- Director Sandberg Richard A sold $77,784 worth of shares (3,134 units at $24.82), decreasing direct ownership by 20% to 8,142 units (SEC Form 4)
- Precipio Announces Q1 2026 Financial Results
- SEC Form 10-Q filed by Precipio Inc.
- Management team's 2025 market-based Options have vested
- Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Precipio Announces Q1-2026 Shareholder Update Call
- SEC Form DEFA14A filed by Precipio Inc.
- SEC Form DEF 14A filed by Precipio Inc.